Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people
暂无分享,去创建一个
Ran Tao | Robert Clarke | Yiping Chen | Yu Guo | Liming Li | Zhengming Chen | R. Collins | R. Peto | R. Clarke | Zhengming Chen | Junshi Chen | Yu Guo | Liming Li | Z. Bian | Yiping Chen | Liangcai Ma | Rory Collins | Richard Peto | Qiuli Zhang | Zheng Bian | Junshi Chen | Liangcai Ma | Qiuli Zhang | Xianhai Pan | Kunxiang Shi | Huarong Sun | R. Tao | Huarong Sun | X. Pan | Kunxiang Shi
[1] S. Barber,et al. Development and status of health insurance systems in China. , 2011, The International journal of health planning and management.
[2] M. Plummer. Improved estimates of floating absolute risk , 2004, Statistics in medicine.
[3] S. Yusuf,et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey , 2011, The Lancet.
[4] H. Bekedam,et al. Controlling cost escalation of healthcare: making universal health coverage sustainable in China , 2012, BMC Public Health.
[5] F. Lampe,et al. Validity of a self-reported history of doctor-diagnosed angina. , 1999, Journal of clinical epidemiology.
[6] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[7] Martin O'Flaherty,et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. , 2010, JAMA.
[8] Zhengming Chen,et al. Doctor-reported hospital management of acute coronary syndrome in China: A nationwide survey of 1029 hospitals in 30 provinces , 2012 .
[9] R. Collins,et al. Cohort profile: the Kadoorie Study of Chronic Disease in China (KSCDC). , 2005, International journal of epidemiology.
[10] R. Peto,et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.
[11] B. J. Gersh. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2008 .
[12] J. Critchley,et al. Explaining the Increase in Coronary Heart Disease Mortality in Beijing Between 1984 and 1999 , 2004, Circulation.
[13] L. Remennick,et al. Self-Rated Health Status and Health Care Utilization Among Immigrant and Non-Immigrant Israeli Jewish Women , 2001, Women & health.
[14] Simon Capewell,et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. , 2007, The New England journal of medicine.
[15] C. Kooperberg,et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. , 2004, American journal of epidemiology.
[16] M. Landray,et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.
[17] Douglas W Mahoney,et al. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. , 2004, Journal of clinical epidemiology.
[18] M M Bergmann,et al. Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. , 1998, American journal of epidemiology.
[19] M. Inoue,et al. Self-reported stroke and myocardial infarction had adequate sensitivity in a population-based prospective study JPHC (Japan Public Health Center)-based Prospective Study. , 2009, Journal of clinical epidemiology.
[20] S. Yusuf,et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.
[21] V. V. Ivanenko,et al. Monday, 27 August 2012 , 2012 .
[22] P. Renjen. Secondary Prevention of Ischemic Stroke and Tia , 2008 .
[23] Simon Capewell,et al. Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000 , 2004, Circulation.
[24] Alan D. Lopez,et al. Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India , 2009, Circulation.
[25] R. John. Crowding out effect of tobacco expenditure and its implications on household resource allocation in India. , 2008, Social science & medicine.
[26] R. Collins,et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. , 2011, International journal of epidemiology.
[27] A. Algra,et al. Self‐rated health status as a risk factor for future vascular events and mortality in patients with symptomatic and asymptomatic atherosclerotic disease: the SMART study , 2012, Journal of internal medicine.
[28] M. Woodward,et al. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .
[29] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .